(Gastric Cancer) Is Nivolumab + Ipilimumab Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- August 26, 2022
- Read time: 1 minute
On August 3, 2022, Thierry André et al. of Saint-Antoine Hospital published in the medical journal Journal of Clinical Oncology the efficacy and safety results of nivolumab (Opdivo) + ipilimumab (Yervoy) as neoadjuvant chemotherapy followed by nivolumab monotherapy in patients with dMMR and MSI-H locally advanced gastric cancer and gastroesophageal junction adenocarcinoma in the GERCOR NEONIPIGA Phase 2 clinical trial.
The GERCOR NEONIPIGA Phase 2 clinical trial administered nivolumab (2-week cycle, 240 mg per dose, 6 cycles total) + ipilimumab (6-week cycle, 1 mg/kg per dose, 2 cycles total) as preoperative therapy to dMMR and MSI-H locally advanced gastric cancer and gastroesophageal junction adenocarcinoma patients (N=32), followed by postoperative nivolumab (4-week cycle, 480 mg per dose). The primary endpoint was complete response rate.
In this trial, the median patient age was 65.5 years. Clinical staging was cT2-T3N0 (N=9), cT2-T3N1 (N=22), and cT3N1M1 (N=1). Results at a median follow-up of 14.9 months were as follows.
The incidence of Grade 3–4 adverse events during preoperative treatment was 19% (N=6). Among the 29 patients who underwent surgery after treatment, all 29 achieved R0 resection, with a complete response rate of 58.6% (N=17).
Based on the GERCOR NEONIPIGA trial results, Thierry André et al. concluded that nivolumab + ipilimumab as neoadjuvant chemotherapy had good tolerability and demonstrated a high complete response rate.
Source: https://ascopubs.org/doi/full/10.1200/JCO.22.00686
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4